Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Sets Cautious Tone For Prescribing Newly Approved Obesity Drugs

Executive Summary

Agency offers perspective in New England Journal of Medicine that lays out the case for careful use of drugs in a space with medical need but a long history of products with toxic side effects.

You may also be interested in...



Eric Colman, FDA’s Lead Obesity Drug Reviewer, Dies At Age 53

As a reviewer, team leader and deputy director in the Division of Metabolism and Endocrinology Products, Colman spearheaded the agency’s policy development on weight-management products.

FDA Gives Metabolism/Endocrinology Division An Acting Director

Diabetes team leader Jean-Marc Guettier is detailed to replace Mary Parks as director of the Division of Metabolism and Endocrinology Products on a temporary basis as she moves up to Deputy Director of the Office of Drug Evaluation II.

Obesity Intervention: A New Era Of Discovery And Innovation

Device manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel